1.丽珠医药JP-1366片申报上市8月15日，丽珠集团发布公告，公司收到NMPA核准签发的《受理通知书》，公司申请的JP-1366片的境内生产药品注册获药监局受理。公开资料显示，JP-1366片的适应症为反流性食管炎。JP-1366片是一款创新钾离子竞争性酸阻滞剂（P-CAB），可以通过竞争性阻断H(+)、K(+)-ATP酶(质子泵)的K(+)通道，阻滞K(+)与质子泵的结合，抑制胃酸的分泌，...
Source Link1.丽珠医药JP-1366片申报上市8月15日，丽珠集团发布公告，公司收到NMPA核准签发的《受理通知书》，公司申请的JP-1366片的境内生产药品注册获药监局受理。公开资料显示，JP-1366片的适应症为反流性食管炎。JP-1366片是一款创新钾离子竞争性酸阻滞剂（P-CAB），可以通过竞争性阻断H(+)、K(+)-ATP酶(质子泵)的K(+)通道，阻滞K(+)与质子泵的结合，抑制胃酸的分泌，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.